X-18924519-C-T
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 4P and 5B. PP3_StrongBP6BS2
The NM_000292.3(PHKA2):c.1576G>A(p.Asp526Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000147 in 1,208,938 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 57 hemizygotes in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000292.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PHKA2 | NM_000292.3 | c.1576G>A | p.Asp526Asn | missense_variant | 16/33 | ENST00000379942.5 | NP_000283.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PHKA2 | ENST00000379942.5 | c.1576G>A | p.Asp526Asn | missense_variant | 16/33 | 1 | NM_000292.3 | ENSP00000369274 | P1 | |
PHKA2 | ENST00000464455.1 | n.145G>A | non_coding_transcript_exon_variant | 3/3 | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000448 AC: 5AN: 111541Hom.: 0 Cov.: 23 AF XY: 0.0000594 AC XY: 2AN XY: 33689
GnomAD3 exomes AF: 0.0000382 AC: 7AN: 183079Hom.: 0 AF XY: 0.0000296 AC XY: 2AN XY: 67543
GnomAD4 exome AF: 0.000158 AC: 173AN: 1097397Hom.: 0 Cov.: 30 AF XY: 0.000152 AC XY: 55AN XY: 362771
GnomAD4 genome AF: 0.0000448 AC: 5AN: 111541Hom.: 0 Cov.: 23 AF XY: 0.0000594 AC XY: 2AN XY: 33689
ClinVar
Submissions by phenotype
Glycogen storage disease IXa1 Uncertain:3
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics Laboratory, University Hospital Schleswig-Holstein | Jun 18, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 07, 2023 | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 526 of the PHKA2 protein (p.Asp526Asn). This variant is present in population databases (rs778051353, gnomAD 0.009%). This missense change has been observed in individual(s) with clinical features of glycogen storage disease type IXa and/or ketotic hypoglycemia symptoms (PMID: 34117828; Invitae). ClinVar contains an entry for this variant (Variation ID: 566810). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on PHKA2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Aug 05, 2021 | - - |
PHKA2-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 04, 2024 | The PHKA2 c.1576G>A variant is predicted to result in the amino acid substitution p.Asp526Asn. This variant has been reported in an individual with ketotic hypoglycemia; however, a similarly affected family member did not carry the variant (Benner et al 2021. PubMed ID: 34117828). This variant is reported in 0.0087% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 01, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at